Diabetic Retinopathy Drug Market Share

Regionally, the diabetic retinopathy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. North America industry is estimated to hold largest revenue share by 2036, driven by supportive reimbursement policies covering treatment costs, sophisticated healthcare infrastructure, and allocation of substantial healthcare expenditure by government. In addition to this, Europe is the second largest shareholder in the market attributing to the increasing obese population in the region, who are prone to diabetes and other related vision disorders. It is calculated that around 3-4% of Europeans are diagnosed with diabetic retinopathy every year.

APAC Market Analysis

Moreover, the market in Asia Pacific is predicted to witness a notable growth during the forecast period as a result of a huge patient pool, growing elderly populace and the rise in innovations for treatment of diabetic retinopathy. The growth of the market in this region is expected to be steered majorly by nations such as China and Japan owing to the escalating per capita income and significant developments in the medical sector.

Frequently Asked Questions (FAQ)

Rising occurrence of diabetes and growing technological advancements for retinopathy treatment to fuel market growth.

The market is anticipated to attain a noteworthy CAGR over the forecast period, i.e., 2021 â€“ 2029.

Lack of skilled ophthalmologists in lower income economies is estimated to hamper the market growth.

Asia Pacific is estimated to provide more market growth opportunities on the back of increasing target patient pool and growing elderly population in the region.

The major players in the market are Pfizer Inc. Bayer AG, Abbott Laboratories, Novartis AG, and others.

Diabetic Retinopathy Drug Market Share